Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension

RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. OBJECTIVE:We hypothesized that HDAC inhibition attenu...

Full description

Saved in:
Bibliographic Details
Published inCirculation research Vol. 112; no. 7; pp. 1004 - 1012
Main Authors Lee, Hae-Ahm, Lee, Dong-Youb, Cho, Hyun-Min, Kim, Sang-Yeob, Iwasaki, Yasumasa, Kim, In Kyeom
Format Journal Article
LanguageEnglish
Published United States American Heart Association, Inc 29.03.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. OBJECTIVE:We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. METHODS AND RESULTS:Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. CONCLUSIONS:These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats.
AbstractList RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. OBJECTIVE:We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. METHODS AND RESULTS:Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. CONCLUSIONS:These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats.
RATIONALEInhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive.OBJECTIVEWe hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats.METHODS AND RESULTSExpression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids.CONCLUSIONSThese results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats.
Rationale: Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. Objective: We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. Methods and Results: Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. Conclusions: These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats.
Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats. Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats.
Author Lee, Hae-Ahm
Kim, In Kyeom
Cho, Hyun-Min
Kim, Sang-Yeob
Lee, Dong-Youb
Iwasaki, Yasumasa
AuthorAffiliation From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.)
AuthorAffiliation_xml – name: From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.)
Author_xml – sequence: 1
  givenname: Hae-Ahm
  surname: Lee
  fullname: Lee, Hae-Ahm
  organization: From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.)
– sequence: 2
  givenname: Dong-Youb
  surname: Lee
  fullname: Lee, Dong-Youb
– sequence: 3
  givenname: Hyun-Min
  surname: Cho
  fullname: Cho, Hyun-Min
– sequence: 4
  givenname: Sang-Yeob
  surname: Kim
  fullname: Kim, Sang-Yeob
– sequence: 5
  givenname: Yasumasa
  surname: Iwasaki
  fullname: Iwasaki, Yasumasa
– sequence: 6
  givenname: In
  surname: Kim
  middlename: Kyeom
  fullname: Kim, In Kyeom
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23421989$$D View this record in MEDLINE/PubMed
BookMark eNqFUU1vEzEQtVARTQM_AeQjly322mbj4yptSaRWoBDOK8c7Zg2OvdjeVvk5_FOcppQjp9HTvA_NvAt05oMHhN5ScknpR_phud4sN9df21VbMLtkhJKGvkAzKmpecdHQMzQjhMiqYYyco4uUfhBCOavlK3ReM15TuZAz9HtlUy7O-AqUhnxwKgFe-8HubLbB4zZn8JPKkPA2Kp90tONxoRxudbb3Nh9wMPjOeojKBR1itjrYHm9Aw5hDxNshhun7gNc5FcljxKOz8j3-EuEefFlclenCuC_gaLc6jBBLcCrE1-ilUS7Bm6c5R99urrfLVXX7-dN62d5WulxMK9UraahSQhBeg16AViCU4kIYtgAlmDFES9bXZtcb1Te9NI3ecWMoYTUXks3R-5PvGMOvCVLu9jZpcE55CFPqKKtpIzkv_5wjcaLqGFKKYLox2r2Kh46S7thO96-dgll3aqfo3j1FTLs99M-qv3UUgjwRHoLLENNPNz1A7AZQLg__Mf8DI1ql2g
CitedBy_id crossref_primary_10_1016_j_steroids_2014_05_017
crossref_primary_10_1016_j_bbadis_2016_08_011
crossref_primary_10_1038_s41569_019_0235_9
crossref_primary_10_1016_j_semnephrol_2020_01_005
crossref_primary_10_1074_jbc_M113_505115
crossref_primary_10_1146_annurev_pharmtox_010814_124302
crossref_primary_10_2174_1570180819666220527160528
crossref_primary_10_18632_oncotarget_2371
crossref_primary_10_4196_kjpp_2016_20_5_477
crossref_primary_10_1111_jcmm_14188
crossref_primary_10_3346_jkms_2017_32_11_1738
crossref_primary_10_1016_j_vph_2015_04_006
crossref_primary_10_48198_NJPAS_20_A07
crossref_primary_10_2174_1389557522666220217103441
crossref_primary_10_1016_j_ejphar_2015_10_035
crossref_primary_10_1097_JCP_0000000000000510
crossref_primary_10_1111_febs_16695
crossref_primary_10_1210_me_2014_1002
crossref_primary_10_1371_journal_pone_0136801
crossref_primary_10_1016_j_compbiomed_2023_107481
crossref_primary_10_1016_j_heliyon_2024_e33997
crossref_primary_10_1038_s41598_019_52762_w
crossref_primary_10_1042_BSR20193995
crossref_primary_10_1186_s40885_019_0118_8
crossref_primary_10_1038_s41440_020_00548_3
crossref_primary_10_3109_13813455_2016_1151892
crossref_primary_10_4068_cmj_2016_52_1_1
crossref_primary_10_1016_j_jsbmb_2014_04_015
crossref_primary_10_1096_fj_201801151R
crossref_primary_10_3390_life14010023
crossref_primary_10_1016_j_biopha_2020_110503
crossref_primary_10_3389_fmed_2020_00475
crossref_primary_10_1016_j_pharmthera_2014_02_012
crossref_primary_10_1016_j_steroids_2023_109291
crossref_primary_10_1161_CIRCRESAHA_118_311342
crossref_primary_10_1097_FJC_0000000000001372
crossref_primary_10_11131_2014_101092
crossref_primary_10_1002_hep_27940
crossref_primary_10_4196_kjpp_2020_24_4_319
crossref_primary_10_1111_1440_1681_12377
crossref_primary_10_1111_1440_1681_12614
crossref_primary_10_1016_j_biopha_2020_111162
crossref_primary_10_1007_s00210_019_01749_5
crossref_primary_10_1002_cai2_114
crossref_primary_10_3389_fendo_2021_679655
crossref_primary_10_3390_foods10061288
crossref_primary_10_1016_j_pharmthera_2016_07_004
crossref_primary_10_1097_HJH_0000000000003143
crossref_primary_10_3390_bioengineering9120798
crossref_primary_10_1111_jsm_12522
crossref_primary_10_1210_en_2014_1565
crossref_primary_10_1016_j_ejmech_2018_08_081
crossref_primary_10_1016_j_jare_2024_02_003
crossref_primary_10_1007_s00210_016_1246_2
crossref_primary_10_4070_kcj_2016_0266
crossref_primary_10_1111_and_12465
crossref_primary_10_1016_j_bcp_2022_115111
crossref_primary_10_4196_kjpp_2018_22_1_23
crossref_primary_10_1038_s41440_019_0332_5
crossref_primary_10_1161_HYPERTENSIONAHA_118_11171
crossref_primary_10_1111_bph_14837
crossref_primary_10_1111_jog_15844
crossref_primary_10_1038_ijo_2017_166
crossref_primary_10_1210_en_2015_2055
crossref_primary_10_1530_JME_15_0122
crossref_primary_10_1152_ajpendo_00267_2017
crossref_primary_10_1021_acs_jmedchem_0c01676
crossref_primary_10_1016_j_ejphar_2021_173988
crossref_primary_10_3390_ijms18081794
crossref_primary_10_1007_s11010_020_04031_y
crossref_primary_10_1161_HYPERTENSIONAHA_124_22072
crossref_primary_10_1016_j_bbadis_2015_05_008
crossref_primary_10_3390_ijms232012592
crossref_primary_10_1161_HYPERTENSIONAHA_123_21755
crossref_primary_10_4196_kjpp_2015_19_5_467
crossref_primary_10_1155_2017_8208065
crossref_primary_10_3390_ijms19113539
crossref_primary_10_3389_fmolb_2021_667990
crossref_primary_10_33549_physiolres_934110
crossref_primary_10_1161_CIRCRESAHA_114_305054
crossref_primary_10_1161_HYPERTENSIONAHA_115_05962
crossref_primary_10_1111_bph_15719
crossref_primary_10_1124_mol_114_096974
crossref_primary_10_1097_HJH_0000000000001081
crossref_primary_10_1155_2014_641979
crossref_primary_10_5483_BMBRep_2015_48_3_242
Cites_doi 10.1210/er.2007-0030
10.1210/me.2004-0537
10.1152/ajpheart.01096.2001
10.1253/circj.CJ-09-0050
10.1016/j.molcel.2006.04.019
10.1111/j.1471-4159.2008.05575.x
10.1158/1541-7786.MCR-07-0324
10.1016/j.biopha.2006.07.082
10.1111/j.1476-5381.2010.00637.x
10.1038/nm.1879
10.1161/hypertensionaha.110.154567
10.1210/endo.138.3.4994
10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
10.1210/en.2004-1674
10.1074/jbc.M100800200
10.1056/NEJM199909023411001
10.1074/jbc.M110.185488
10.1161/01.hyp.0000174593.88899.68
10.1161/01.res.0000037983.07158.b1
10.1161/circresaha.111.258426
10.1073/pnas.0407008101
10.1016/S1097-2765(01)00414-2
10.1056/NEJMoa030207
10.1002/jcb.21640
10.1158/0008-5472.CAN-03-0799
10.1038/47412
10.1210/jcem.83.12.5470
10.1042/bse0400011
10.1621/nrs.05012
10.1146/annurev.biochem.76.052705.162114
10.1016/j.cell.2011.03.043
10.1210/me.2005-0089
10.1161/hypertensionaha.111.182428
10.1096/fj.08-117697
10.1210/me.2010-0170
10.1161/circulationaha.106.625467
10.1074/jbc.M409053200
10.1016/j.bcp.2006.05.024
ContentType Journal Article
Copyright 2013 American Heart Association, Inc.
Copyright_xml – notice: 2013 American Heart Association, Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1161/CIRCRESAHA.113.301071
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4571
EndPage 1012
ExternalDocumentID 10_1161_CIRCRESAHA_113_301071
23421989
10.1161/CIRCRESAHA.113.301071
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
.Z2
01R
0R
1J1
29B
2WC
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O
7O~
AAAXR
AAMOA
AAMTA
AAPBV
AARTV
AAXQO
ABBUW
ABFLS
ABOCM
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACPRK
ACWDW
ACWRI
ACXNZ
ADACO
ADBBV
AE3
AENEX
AFUWQ
AHMBA
AHULI
AHVBC
AIJEX
AJIOK
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
AWKKM
BAWUL
BOYCO
BQLVK
C45
CS3
DIK
DU5
DUNZO
E.X
E3Z
EBS
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FL-
FRP
FW0
GX1
H0
H0~
H13
HZ
IKYAY
IN
IN~
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
LI0
N9A
N~7
N~B
O0-
O9-
OAG
OAH
OB2
ODA
OHASI
OK1
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OWW
OWY
OXXIT
P2P
PQEST
PQQKQ
RAH
RHF
RIG
RLZ
RSW
S4R
S4S
UPT
V2I
WH7
WOQ
WOW
X
X3V
X3W
Z2
ZA5
---
-~X
.-D
.3C
0R~
18M
AAAAV
AAGIX
AAHPQ
AAIQE
AASOK
ABDIG
ABJNI
ABQRW
ACCJW
ACGFO
ACILI
ACNWC
ADGGA
ADHPY
AE6
AEETU
AFDTB
AGINI
AHOMT
AHQNM
AINUH
AJNWD
AMNEI
CGR
CUY
CVF
DIWNM
ECM
EIF
FCALG
HZ~
IKREB
NPM
T8P
TEORI
TR2
VVN
W3M
W8F
YFH
YOC
ZFV
ZZMQN
AAYXX
AJZMW
CITATION
7X8
ID FETCH-LOGICAL-c5241-ada9f1aa55042ec8ecae5aa455f38ea53ff0c93d2fbdfad7d9f7cb4ff10324593
ISSN 0009-7330
IngestDate Fri Aug 16 02:02:52 EDT 2024
Fri Aug 23 03:51:58 EDT 2024
Thu May 23 23:17:25 EDT 2024
Thu Aug 13 19:50:26 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5241-ada9f1aa55042ec8ecae5aa455f38ea53ff0c93d2fbdfad7d9f7cb4ff10324593
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.113.301071
PMID 23421989
PQID 1321794473
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1321794473
crossref_primary_10_1161_CIRCRESAHA_113_301071
pubmed_primary_23421989
wolterskluwer_health_10_1161_CIRCRESAHA_113_301071
ProviderPackageCode L-C
C45
7O~
AARTV
OLH
ASCII
OLG
AAMOA
ODA
ABZAD
ABBUW
JK3
JK8
H0~
1J1
OLV
OLU
OLW
OLZ
OLY
F2K
F2M
F2L
F2N
OHASI
AHVBC
FL-
KMI
K8S
OVLEI
AJIOK
OPUJH
V2I
S4R
S4S
4Q1
DUNZO
OAG
4Q2
OVDNE
4Q3
AMJPA
OAH
OVD
71W
AHULI
OB2
ACEWG
.Z2
N~7
IKYAY
OVIDH
AWKKM
40H
N~B
X3V
X3W
ACDDN
ACWRI
BOYCO
AIJEX
AAXQO
AAMTA
AAAXR
E.X
OWW
OWY
01R
ACXNZ
OL1
ABXVJ
IN~
KD2
OXXIT
77Y
ACWDW
FW0
PublicationCentury 2000
PublicationDate 2013-March-29
2013-Mar-29
2013-03-29
20130329
PublicationDateYYYYMMDD 2013-03-29
PublicationDate_xml – month: 03
  year: 2013
  text: 2013-March-29
  day: 29
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Circulation research
PublicationTitleAlternate Circ Res
PublicationYear 2013
Publisher American Heart Association, Inc
Publisher_xml – name: American Heart Association, Inc
References e_1_3_5_28_2
e_1_3_5_27_2
e_1_3_5_26_2
e_1_3_5_25_2
e_1_3_5_24_2
e_1_3_5_23_2
e_1_3_5_22_2
e_1_3_5_21_2
e_1_3_5_29_2
e_1_3_5_2_2
e_1_3_5_40_2
e_1_3_5_8_2
e_1_3_5_20_2
e_1_3_5_7_2
e_1_3_5_9_2
e_1_3_5_4_2
e_1_3_5_3_2
e_1_3_5_6_2
e_1_3_5_5_2
e_1_3_5_17_2
e_1_3_5_39_2
e_1_3_5_16_2
e_1_3_5_38_2
e_1_3_5_15_2
e_1_3_5_37_2
e_1_3_5_14_2
e_1_3_5_36_2
e_1_3_5_12_2
e_1_3_5_35_2
e_1_3_5_13_2
e_1_3_5_34_2
e_1_3_5_10_2
e_1_3_5_11_2
e_1_3_5_32_2
Fuqua SA (e_1_3_5_33_2) 2000; 60
e_1_3_5_19_2
e_1_3_5_18_2
e_1_3_5_31_2
e_1_3_5_30_2
References_xml – ident: e_1_3_5_16_2
  doi: 10.1210/er.2007-0030
– ident: e_1_3_5_31_2
  doi: 10.1210/me.2004-0537
– ident: e_1_3_5_19_2
  doi: 10.1152/ajpheart.01096.2001
– ident: e_1_3_5_30_2
  doi: 10.1253/circj.CJ-09-0050
– ident: e_1_3_5_12_2
  doi: 10.1016/j.molcel.2006.04.019
– ident: e_1_3_5_23_2
  doi: 10.1111/j.1471-4159.2008.05575.x
– ident: e_1_3_5_22_2
  doi: 10.1158/1541-7786.MCR-07-0324
– ident: e_1_3_5_14_2
  doi: 10.1016/j.biopha.2006.07.082
– ident: e_1_3_5_2_2
  doi: 10.1111/j.1476-5381.2010.00637.x
– ident: e_1_3_5_40_2
  doi: 10.1038/nm.1879
– ident: e_1_3_5_3_2
  doi: 10.1161/hypertensionaha.110.154567
– ident: e_1_3_5_36_2
  doi: 10.1210/endo.138.3.4994
– ident: e_1_3_5_24_2
  doi: 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
– ident: e_1_3_5_37_2
  doi: 10.1210/en.2004-1674
– ident: e_1_3_5_34_2
  doi: 10.1074/jbc.M100800200
– ident: e_1_3_5_38_2
  doi: 10.1056/NEJM199909023411001
– ident: e_1_3_5_11_2
  doi: 10.1074/jbc.M110.185488
– ident: e_1_3_5_18_2
  doi: 10.1161/01.hyp.0000174593.88899.68
– ident: e_1_3_5_8_2
  doi: 10.1161/01.res.0000037983.07158.b1
– ident: e_1_3_5_20_2
  doi: 10.1161/circresaha.111.258426
– ident: e_1_3_5_28_2
  doi: 10.1073/pnas.0407008101
– ident: e_1_3_5_10_2
  doi: 10.1016/S1097-2765(01)00414-2
– ident: e_1_3_5_39_2
  doi: 10.1056/NEJMoa030207
– ident: e_1_3_5_32_2
  doi: 10.1002/jcb.21640
– ident: e_1_3_5_21_2
  doi: 10.1158/0008-5472.CAN-03-0799
– ident: e_1_3_5_4_2
  doi: 10.1038/47412
– ident: e_1_3_5_26_2
  doi: 10.1210/jcem.83.12.5470
– ident: e_1_3_5_13_2
  doi: 10.1042/bse0400011
– ident: e_1_3_5_17_2
  doi: 10.1621/nrs.05012
– volume: 60
  start-page: 4026
  year: 2000
  ident: e_1_3_5_33_2
  article-title: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
  publication-title: Cancer Res
  contributor:
    fullname: Fuqua SA
– ident: e_1_3_5_5_2
  doi: 10.1146/annurev.biochem.76.052705.162114
– ident: e_1_3_5_9_2
  doi: 10.1016/j.cell.2011.03.043
– ident: e_1_3_5_29_2
  doi: 10.1210/me.2005-0089
– ident: e_1_3_5_27_2
  doi: 10.1161/hypertensionaha.111.182428
– ident: e_1_3_5_25_2
  doi: 10.1096/fj.08-117697
– ident: e_1_3_5_35_2
  doi: 10.1210/me.2010-0170
– ident: e_1_3_5_6_2
  doi: 10.1161/circulationaha.106.625467
– ident: e_1_3_5_7_2
  doi: 10.1074/jbc.M409053200
– ident: e_1_3_5_15_2
  doi: 10.1016/j.bcp.2006.05.024
SSID ssj0014329
Score 2.4375956
Snippet RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats...
Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and...
Rationale: Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive...
RATIONALEInhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats...
SourceID proquest
crossref
pubmed
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage 1004
SubjectTerms Acetylation - drug effects
Aldosterone - pharmacology
Animals
Desoxycorticosterone - pharmacology
Disease Models, Animal
DNA Polymerase II - metabolism
Enzyme Inhibitors - pharmacology
Gene Expression - drug effects
HEK293 Cells
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - genetics
Histone Deacetylases - metabolism
Humans
Hypertension, Renal - chemically induced
Hypertension, Renal - prevention & control
Male
Mineralocorticoids - pharmacology
Nephrectomy
Promoter Regions, Genetic - genetics
Rats
Rats, Sprague-Dawley
Receptors, Mineralocorticoid - genetics
Receptors, Mineralocorticoid - metabolism
Transcription, Genetic - drug effects
Valproic Acid - pharmacology
Title Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension
URI https://www.ncbi.nlm.nih.gov/pubmed/23421989
https://search.proquest.com/docview/1321794473
Volume 112
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bitswEBXpFkpLKb03vaFC34LSWJYT-zFkW5yW9KFkYd-MLEu7oaxdEoey_Zt-YP-hM7ZsK5vQy76YxNiSzTkeaaQzM4S8VWOjMi5DNvb1iMF4rVgUBIZ5WQAW05iR5hjgvPg8jk_Ex9PgtNf75aiWtmU6VD8OxpVcB1U4B7hilOx_INs2CifgN-ALR0AYjv-EcZXjI0flj1S6vISJMCohz1dppcMaTEuYEG9xMlnnMG8MBKKibNUIVMCsqszTBfih0EOxwoBFFLsU68HSVvGZlxu4peqibPTLNvnTxtUdVdsC4NmuK128RbzJg7BaK1srbGBTDLVL0VYOFEvNpucXV84eF_kZA6uUdlKEan03vtzmbLFyZAQX9Ro3Xq6L1F3QwOISPuOd2Wx3qmJ4kNJl6Z46FCeIbOLbjR1tLTgXTAR1XZfWxHvc4fLEMdiYMM8Z_DHb2eGBZYwDy2z-ZQYfxjSeYi2cIRjHke1oN2f3X-64QW7ySRTgWsHx_FO76SV8HjWF__CtbMAZNPTuYDO7U6k9_-gOufu9QMnF5msVceHMm5b3yT3r8NBpzd4HpKfzh-TWwko6HpGflsTUITHtSEw7EtMrJKYNiWlh6B6JaUNiaklMgcTUITEFEtOGxNQhMTbnkvgxOfnwfjmLma0bwhSA7zGZych4UoLzLbhWoVZSB1IKsEF-qGXggwlSkZ9xk2ZGZpMsMhOVCmMwuaQIIv8JOcrhxZ8RKqSBqzMejtJQCGWiMIvCyIzAjRFGerpPhg0Eybc6PUxSudVjL-kwg_9-UmPWJ28aoBIw5Lg7J3NdbDeJ53McHMXE75OnNYJtk9wXHMWNfcJ3IE3qYOk_d_n8Oje9ILe7b_MlOSrXW_0Kpt9l-roi7W_gsN8g
link.rule.ids 315,786,790,27957,27958
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histone+Deacetylase+Inhibition+Attenuates+Transcriptional+Activity+of+Mineralocorticoid+Receptor+Through+Its+Acetylation+and+Prevents+Development+of+Hypertension&rft.jtitle=Circulation+research&rft.au=Lee%2C+Hae-Ahm&rft.au=Lee%2C+Dong-Youb&rft.au=Cho%2C+Hyun-Min&rft.au=Kim%2C+Sang-Yeob&rft.date=2013-03-29&rft.pub=American+Heart+Association%2C+Inc&rft.issn=0009-7330&rft.eissn=1524-4571&rft.volume=112&rft.issue=7&rft.spage=1004&rft.epage=1012&rft_id=info:doi/10.1161%2FCIRCRESAHA.113.301071&rft.externalDocID=10.1161%2FCIRCRESAHA.113.301071
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7330&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7330&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7330&client=summon